For instance, GAT inhibitors, that have long been used clinically as antiepileptics (e.g., Tiagabine) to increase GABA function [123], could be tested for their potential to diminish DA signalling and/or GAT function in Huntington’s disease. The gene discussed is GLYAT; the disease is juvenile Huntington disease.